Stockholders Approve New Equity Incentive Plan Authorizing Significant Share Pool

summarizeSummary

Stockholders approved the 2026 Equity Incentive Plan, authorizing 650,000 new shares plus rollover shares for future compensation, representing a notable potential for dilution.

check_boxKey Events · Corporate Governance and Compliance · PTGX

• 2026 Equity Incentive Plan Approved

  Stockholders approved the adoption of the 2026 Equity Incentive Plan, replacing the 2016 plan, at the Annual Meeting held on June 17, 2026. This follows the proposal in the DEF 14A filed on April 28, 2026.

• Significant Share Authorization

  The new plan authorizes 650,000 new shares, plus any shares remaining from the 2016 plan and shares from outstanding awards that expire or are forfeited. This represents a notable potential for future dilution, with the 650,000 new shares alone equating to approximately 1.01% of current outstanding shares.

• Routine Proposals Approved

  Stockholders also approved the election of two Class I director nominees, the advisory compensation of named executive officers, and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026.

auto_awesomeAnalysis · PTGX · Life Sciences

Protagonist Therapeutics' stockholders approved the 2026 Equity Incentive Plan, which authorizes a substantial pool of shares for future compensation. This plan includes 650,000 new shares, in addition to shares remaining from the prior 2016 plan and those that may return from outstanding awards. While equity incentive plans are standard for talent attraction and retention, the authorization of 650,000 new shares represents approximately 1.01% of the company's outstanding stock, indicating a notable potential for future dilution. This approval follows the company's proposal in a DEF 14A filing on April 28, 2026, and occurs while the stock is trading near its 52-week high, and against a backdrop of significant insider selling over the past 90 days.